Skip to Content

'
Zhongxing Liao, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Clinical Medical Director, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

My research interests focus on improving the therapeutic ratio of radiation therapy for thoracic malignancies through translational research. More specifically, I am seeking to improve the efficacy and reduce the toxicity of chemoradiation therapy for lung and esophageal cancers by using molecular targeting strategies; by using advanced radiation delivery technologies; by generating and using models for predicting risks of normal tissue toxicity; by reducing that toxicity with adaptive modification of radiation parameters based on biomarkers such as SNPs and serum levels of inflammatory cytokines,  by reducing the symptom burden and improving patients quality of life using integrative medicine,  and ultimately, by developing strategies to practice  highly personalized treatments. 

 

1.            Translational research to improve chemoradiation therapy for lung cancer

One way of improving the therapeutic ratio in thoracic radiation therapy is to enhance tumor cell radiosensitivity through the use of molecular targeted therapy. For the past several years, I have extensively explored the potential of selective cyclooxygenase-2 (COX-2) inhibitors in combination with radiation and chemoradiation therapy for this purpose. These clinical studies are an outgrowth of earlier laboratory investigations performed in collaboration with Dr. Luka Milas and other colleagues in the Department of Experimental Radiation Oncology (ERO). I was the first at M. D. Anderson Cancer Center to initiate a United States–based clinical trial using a selective COX-2 inhibitor, celecoxib, in combination with radiation therapy for the treatment of surgically unresectable non-small cell lung cancer (NSCLC).  This study was supported by a peer-reviewed grant from the Radiological Society of North America. This clinical trial was completed in 2 years, and the results have been published in Clinical Cancer Research (Appendix 1). With the information derived from this trial, I subsequently acted as Co-Principal Investigator on a follow-up phase I trial of celecoxib and concurrent chemoradiation for patients with stage III NSCLC. This clinical trial has completed accrual, and data analysis is expected to be completed this year.

  

2.            Translational research to reduce treatment-related toxicity

Another strategy for improving the therapeutic ratio of thoracic radiation therapy is to reduce treatment-related injury to normal tissues. Treatment-related toxicity, especially pneumonitis, is one of the major dose-limiting toxicities associated with thoracic radiation therapy. My interest in research on normal lung injury induced by thoracic radiation grew from the time I was a postdoctoral fellow in Dr. Elizabeth Travis’s laboratory in the Department of ERO. In that work, I investigated the effect of partial lung irradiation in mice and demonstrated that lung injury from radiation was dependent on the radiation dose and the volume and region of exposed lung. The published results from this study are widely considered by experts in the field to be seminal findings on this topic.

 

I havefound that using advanced radiation delivery technologies such as intensity-modulated radiation (IMRT) to reduce the dose and volume of the normal lung irradiated could drastically reduce clinical symptomatic lung toxicity. Most recently,  I, as the principal investigator, have designed and led "A Bayesian randomized trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, with Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence".  The first randomized trial on the history of proton treatment for lung cancer . The overall goal of this effort is to determine whether personalized medicine that includes the use of predictive treatment-related toxicity risk models and treatment adaptation will lead to improved outcome for patients with locally advanced NSCLC. This research has already generated more than 70 peer-reviewed publications by our group on which I serve as author or coauthor, and several of these publications are frequently referred to by practicing thoracic radiation oncologists both nationally and internationally.

3.                  Research on symptoms and survivorship

Additional collaborative activities have included my work with Drs. Charles Cleeland and Xin Shelley Wang in the Department of Symptom Research. I was a Co-Principal Investigator on an R21 grant (PI-Xin S. Wang) that investigated possible correlations of inflammatory cytokines with symptom burden in patients with lung cancer who underwent chemoradiation. The final results were published in the Journal of Clinical Oncology.

 

I am the pricipal invesigtor and one of the co-investigators in another R21 grant (PI- Xin Shelley Wang) proposal, “Inflammatory Cytokines–Associated Symptom Burden in NSCLC Patients Receiving CXRT,” that was recently funded by the NIH, effective August 1, 2008.   This grant will focus on assessing symptoms and investigating the biological basis for the symptom burden experienced by patients treated in the adaptive randomized trial of 3-dimensional conformal vs intensity-modulated therapy mentioned in item 3. I have also been invited to participate as a Co-Investigator on another NIH-funded R01 grant (PI-Cleeland), “Reducing the Symptom Burden Produced by Aggressive Cancer Therapies,” another randomized clinical trial designed to test if the adaptive medical interventional therapy approaches can reduce the symptom burden experienced during and after such treatments. 

 

4.         Research on integrative oncology and international collaboration

I am Co-Principal Investigator on a clinical research project in integrative and alternative medicine, initially supported by an R21 grant (PI, Dr. Lorenzo Cohen) and later by a U19 grant funded at $2 million over 4 years by the NCI. The aim of this research is to promote and establish international collaboration in assessing the role of complementary and alternative medicine in cancer patient care. The award of the U19, which supports 10% of my salary via the administrative core, was based on my successful collaborations with Fudan University Cancer Hospital in Shanghai, China. In 2007, I was invited to organize a symposium on integrative oncology for the International Congress of Radiation Research in San Francisco. I also served on the Scientific Committee of the Society of Integrative Oncology, which held an international meeting on this topic in April 2008 in Shanghai, China.

 

Education & Training

Degree-Granting Education

1982 Hunan Medical University, Changsha, Hunan, China, MD, Medicine

Postgraduate Training

7/1995-6/1999 Clinical Residency, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Alan Pollack
7/1994-6/1995 Clinical Internship, Internal Medicine, The University of Kansas School of Medicine-Wichita, Wichita, KS, Dr. Garnold Minns
10/1993-6/1994 Clinical Fellowship, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Patricia Eifel
3/1989-9/1993 Research Fellowship, Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Elizabeth Travis

Board Certifications

6/1999 American Board of Radiology - Radiation Oncology

Experience/Service

Institutional Committee Activities

Member, Data Safety Monitoring Board, 9/2008-8/2010
Member, The Executive Committee for Medical Staff, The University of Texas M. D. Anderson Cancer Center, 1/2007-present
Member, Harris County Health District (HCHD/MDACC) Joint Operation Committee, 1/2007-present
Member, Uncompensated Care Advisory Committee, The University of Texas M. D. Anderson Cancer Center, 1/2007-2009
Member, MDACC/HCHD Quarterly Administrative/Medical Advisory Committee, 1/2007-2009
Member, IRB Data Safety Monitoring Committee, The University of Texas M. D. Anderson Cancer Center, 1/2005-2008
Member, Steering Committee for China, Extramural Program, The University of Texas M. D. Anderson Cancer Center, 6/2004-present
Member, Asia Task Force, Extramural Program, The University of Texas M. D. Anderson Cancer Center, 7/1999-present

Honors and Awards

2011 The Marie Sklodowska-Curie Award-American Association for Women Radiologists, AAWR
2007 Outstanding Contribution to Radiation Oncology Education for China Award, Chinese Society of Therapeutic Radiology and Oncology
2007 Outstanding International Collaboration Award, Chinese Society of Therapeutic Radiology and Oncology

Professional Memberships

American Association of Women Radiologists, Houston
President-Elect, 11/2008-11/2009
American College of Radiology
Member, 1999-present
American Medical Association
Member, 1999-present
American Radium Society, Houston, TX
Member, 1999-present
American Society for Therapeutic Radiology and Oncology
Membership Committee of the Board of Directors, 10/2006-present
American Society of Clinical Oncology
Member, 1999-2009
Harris County Medical Society
Member, 1999-present
Texas Radiology Society
Member, 1999-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, Liao Z, Maru D, Mehran R, Patel S, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Ajani JA. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. In Press.
2. Vinogradskiy Y, Tucker SL, Liao Z, Martel MK. Investigation of the Relationship Between Gross Tumor Volume Location and Pneumonitis Rates Using a Large Clinical Database of Non-Small-Cell Lung Cancer Patients. Int J Radiat Oncol Biol Phys 82(5):1650-8, 4/2012. e-Pub 4/2011. PMID: 21497454.
3. Yin M, Liao Z, Liu Z, Wang LE, O'Reilly M, Gomez D, Li M, Komaki R, Wei Q. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer 118(2):528-35, 1/2012. e-Pub 6/2011. PMCID: PMC3184314.
4. Yin M, Liao Z, Liu Z, Wang LE, Gomez D, Komaki R, Wei Q. Functional Polymorphisms of Base Excision Repair Genes XRCC1 and APEX1 Predict Risk of Radiation Pneumonitis in Patients with Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 81(3):e67-73, 11/2011. e-Pub 3/2011. PMCID: PMC3136565.
5. Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24(6):968-74, 8/2010. e-Pub 3/2010. PMCID: PMC2897921.
6. Liao ZX, Komaki RR, Thames HD, Liu HH, Tucker SL, Mohan R, Martel MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 76(3):775-81, 3/2010. e-Pub 6/2009. PMID: 19515503.
7. Meng ZQ, Garcia MK, Chiang JS, Peng HT, Shi YQ, Fu J, Liu LM, Liao ZX, Zhang Y, Bei WY, Thornton B, Palmer JL, McQuade J, Cohen L. Electro-acupuncture to prevent prolonged postoperative ileus: a randomized clinical trial. World J Gastroenterol 16(1):104-111, 1/2010.
8. Cen P, Correa AM, Lee JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA, Vaporciyan A, Ajani JA. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: Differences in patients' survival after preoperative chemoradiation. Dis Esophagus 22(1):32-41, 11/2009. PMID: 19021684.
9. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R. Pilot study of huachansu in patients with hepatocellular carcinoma, non-small cell lung cancer, or pancreatic cancer. Cancer 115(22):5309-5318, 11/2009.
10. McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, O'Reilly MS, Cox JD, Allen PK, Komaki R. Is sex associated with the outcome of patients treated with radiation for non-small cell lung cancer? Cancer 115(14):3233-3242, 7/2009. PMID: 19472405.
11. Zhang Z, Chen Y, Chen YZ, Jeter M, Hofstetter WL, Ajani J, Swisher SG, Chang JY, Guerrero TM, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with esophageal cancer radiation therapy. J Thor Oncol 4(7):880-888, 7/2009. PMID: 19458557.
12. Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD, Milas L, Wei Q. Single nucleotide polymorphism at rs1982073:T869C of the TGF{beta}1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 27(20):3370-3378, 7/2009. PMID: 19380441.
13. Jin H, Tucker SL, Liu HH, Wei X, Yom SS, Wang S, Komaki R, Chen Y, Martel MK, Mohan R, Cox JD, Liao Z. Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. Radiother Oncol 91(3):427-432, 6/2009. PMID: 18937989.
14. Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, Hofstetter WL, Ajani JA, McAleer MF, Komaki R, Cox JD. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys 74(2):482-489, 6/2009. PMID: 19289262.
15. Gayed I, Gohar S, Liao Z, McAleer M, Bassett R, Yusuf SW. The clinical implications of myocardial perfusion abnormalities in patients with esophageal or lung cancer after chemoradiation therapy. Int J Cardiovasc Imaging 25(5):487-495, 6/2009. PMID: 19234869.
16. Pan X, Zhang X, Li Y, Mohan R, Liao Z. Impact of using different 4D CT data sets to design proton treatment plans for distal esophageal cancer. Int J Radiat Oncol Biol Phys 73(2):601-609, 2/2009. PMID: 19147024.
17. Gayed IW, Liu HH, Wei X, Liao Z, Yusuf SW, Chang JY, Bassett R, Komaki R. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol 4(2):179-184, 2/2009. PMID: 19179893.
18. Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 73(1):119-127, 1/2009. PMID: 18556142.
19. Chang JY, Balter PA, Dong L, Yang Q, Liao ZX, Jeter M, Bucci MK, McAleer MF, Mehran RJ, Roth JA, Komaki R. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 72(4):967-971, 11/2008. PMID: 18954709.
20. Tucker SL, Liu HH, Liao Z, Wei X, Wang S, Jin H, Komaki R, Martel MK, Mohan R. Analysis of radiation pneumonitis risk using a generalized Lyman model. Int J Radiat Oncol Biol Phys 72(2):568-574, 10/2008. PMID: 18793959.
21. Zhang X, Zhao KL, Guerrero TM, McGuire SE, Yaremko B, Komaki R, Cox JD, Hui Z, Li Y, Newhauser WD, Mohan R, Liao Z. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 72(1):278-287, 9/2008. PMCID: PMC2610812.
22. Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, Ajani JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer 113(6):1302-1308, 9/2008. PMID: 18623381.
23. Gayed IW, Chang J, Kim EE, Nuñez R, Chasen B, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol 3(8):858-864, 8/2008.
24. Chi PC, Mawlawi O, Luo D, Liao Z, Macapinlac HA, Pan T. Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation. Int J Radiat Oncol Biol Phys 71(3):890-899, 7/2008. PMID: 18514781.
25. Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 26(28):4551-4556, 6/2008. e-Pub 6/2008. PMID: 18574157.
26. Wang S, Liao Z, Wei Xiong, Liu HH, Tucker SL, Hu C, Ajani JA, Phan A, Swisher SG, Mohan R, Cox JD, Komaki R. Association between systemic chemotherapy prior to chemoradiation and increased risk of treatment related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 3(3):277-282, 3/2008.
27. Wei X, Liu HH, Tucker SL, Wangs, Mohan R, Cox JD, Komaki R, Liao Z. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 70(3):707-714, 3/2008. PMID: 18191334.
28. Chang JY, Dong L, Liu H, Starkschall G, Balter P, Mohan R, Liao Z, Cox JD, Komaki R. Image-Guided radiation therapy for non-small cell lung cancer. J Thorac Oncol 3(2):177-186, 2/2008. PMID: 18303441.
29. Yaremko BP, Guerrero TM, McAleer MF, Bucci MK, Martinez JN, Nguyen LT, Balter PA, Guerra R, Komaki R, Liao Z. Determination of respiratory motion for distal esophagus cancer using four-dimensional computed tomography. Int J Radiat Oncol Biol Phys 70(1):145-153, 1/2008. e-Pub 2007. PMID: 17855008.
30. Izzo JG, Wu X, Wu TT, Huang P, Lee JS, Liao Z, Lee JH, Bhutani MS, Hofstetter W, Maru D, Hung MC, Ajani JA. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus 22(2):127-132, 2008. PMID: 19021681.
31. Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, Walsh GL, Swisher SG, Hofstetter WL, Mehran RJ, Roth JA, Liao Z, Smythe WR. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 84(5):1685-1692; discussion 1692-1693, 11/2007. PMID: 17954086.
32. Rice DC, Smythe WR, Liao Z, Guerrero T, Chang JY, McAleer MF, Jeter MD, Correa A, Vaporciyan AA, Liu HH, Komaki R, Forster KM, Stevens CW. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69(2):350-357, 10/2007. PMID: 17467922.
33. Zhao KL, Liao Z, Bucci MK, Komaki R, Cox JD, Yu ZH, Zhang L, Mohan R, Dong L. Evaluation of respiratory-induced target motion for esophageal tumors at the gastroesophageal junction. Radiother Oncol 84(3):283-289, 9/2007. e-Pub 8/2007. PMID: 17716759.
34. Shioyama Y, Jang SY, Liu HH, Guerrero T, Wang X, Gayed IW, Erwin WD, Liao Z, Chang JY, Jeter M, Yaremko BP, Borghero YO, Cox JD, Komaki R, Mohan R. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 68(5):1349-1358, 8/2007. PMID: 17446001.
35. Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg 84(2):365-373; discussion 374-375, 8/2007. PMID: 17643602.
36. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68(3):779-785, 7/2007. PMID: 17418967.
37. Guerrero T, Johnson V, Hart J, Pan T, Khan M, Luo D, Liao Z, Ajani J, Stevens C, Komaki R. Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lung. Int J Radiat Oncol Biol Phys 68(4):1030-1035, 7/2007. PMID: 17398033.
38. Liu HH, Balter P, Tutt T, Choi B, Zhang J, Wang C, Chi M, Luo D, Pan T, Hunjan S, Starkschall G, Rosen I, Prado K, Liao Z, Chang J, Komaki R, Cox JD, Mohan R, Dong L. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys 68(2):531-540, 6/2007. PMID: 17398035.
39. Davidson SE, Ibbott GS, Prado KL, Dong L, Liao Z, Followill DS. Accuracy of two heterogeneity dose calculation algorithms for IMRT in treatment plans designed using an anthropomorphic thorax phantom. Med Phys 34(5):1850-1857, 5/2007. PMID: 17555266.
40. Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, Wang X, Wang S, Mohan R, Cox JD, Komaki R. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68(1):94-102, 5/2007. PMID: 17321067.
41. Kang Y, Zhang X, Chang JY, Wang H, Wei X, Liao Z, Komaki R, Cox JD, Balter PA, Liu H, Zhu XR, Mohan R, Dong L. 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys 67(3):906-914, 3/2007. PMID: 17293240.
42. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu CS, Mohan R, Cox JD, Komaki. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 66(5):1399-1407, 12/2006.
43. Tucker SL, Liu HH, Wang S, Wei X, Liao Z, Komaki R, Cox JD, Mohan R. Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 66(3):754-761, 11/2006. PMID: 16965865.
44. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, Ajani J, Chao KS. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 12(21):6565-6572, 11/2006. PMID: 17085672.
45. Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 5(11):2844-2850, 11/2006. PMID: 17121931.
46. Hui Z, Li Y, Yu Z, Liao Z. Survey on use of postmastectomy radiotherapy for breast cancer in China. Int J Radiat Oncol Biol Phys 66(4):1135-1142, 11/2006.
47. Gayed IW, Liu HH, Yusuf SW, Komaki R, Wei X, Wang X, Chang JY, Swafford J, Broemeling L, Liao Z. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 47(11):1756-1762, 11/2006. PMID: 17079807.
48. Pan T, Mawlawi O, Luo D, Liu HH, Chi PC, Mar MV, Gladish G, Truong M, Erasmus J, Liao Z, Macapinlac HA. Attenuation correction of PET cardiac data with low-dose average CT in PET/CT. Med Phys 33(10):3931-3938, 10/2006. PMID: 17089855.
49. Wang SL, Liao Z, Liu H, Ajani J, Swisher S, Cox JD, Komaki R. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol 12(34):5501-5508, 9/2006. PMID: 17006988.
50. Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM, Cleeland CS. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 24(27):4485-4491, 9/2006. PMID: 16983118.
51. Wei X, Liu HH, Tucker SL, Liao Z, Hu C, Mohan R, Cox JD, Komaki R. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66(1):100-107, 9/2006. PMID: 16839700.
52. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24(23):3789-3798, 8/2006. PMID: 16785472.
53. Erasmus JJ, Munden RF, Truong MT, Ho JJ, Hofstetter WL, Macapinlac HA, Correa AM, Wu TT, Bruzzi JF, Marom EM, Sabloff BS, Ajani JA, Komaki R, Liao Z, Lee JH, Fukami N, Bresalier R, Swisher SG. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol 1(5):478-486, 6/2006. PMID: 17409902.
54. Hu C, Chang EL, Hassenbusch SJ, Allen PK, Woo SY, Mahajan A, Komaki R, Liao Z. Non-small cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 106(9):1998-2004, 5/2006.
55. Wang S, Liao Z, Chen Y, Chang JY, Jeter M, Guerrero T, Ajani A, Phan A, Swisher S, Allen P, Cox JD, Komaki R. Esophageal cancer located at neck and upper thorax treated with concurrent chemoradiation - a single institutional experience at M. D. Anderson Cancer Center. J Thorac Oncol 1(3):252-259, 3/2006.
56. Wang SL, Liao Z, Vaporciyan AA, Tucker SL, Liu HH, Wei X, Swisher S, Ajani JA, Cox JD, Komaki R. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 64(3):692-699, 3/2006.
57. Liao Z, Liu H, Swisher SG, Wang L, Wu TT, Correa AM, Roth JA, Cox JD, Komaki R, Ajani JA, Wei Q. Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 64(3):700-708, 3/2006. PMID: 16242255.
58. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki R, Rashid A, Hamilton SR, Wu T. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma treated with preoperative chemoradiation. Cancer 106(5):1017-1025, 3/2006.
59. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24(5):748-754, 2/2006. PMID: 16401681.
60. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Bresalier RS, Roth JA, Ajani JA. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 106(3):552-558, 2/2006. PMID: 16353210.
61. Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki R, Liao Z, Phan A, Rice DC, Vaporciayan AA, Walsh Gl, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. Endoscopic ultrasonography-indentified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg 131(1):65-72, 1/2006.
62. Rohatgi PR, Correa AM, Swisher SG, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lee JH, Rice DC, Roth JA, Ajani JA. Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. Dis Esophagus 19(3):152-157, 2006. PMID: 16722991.
63. Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 104(11):2365-2372, 12/2005.
64. Liu HH, Guerrero T, Liao Z, Tucker S, Wang X, Bonnen M, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R, Stevens C, Chandra A. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 77(3):247-253, 12/2005.
65. Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, Murshed H, Bonnen MD, Garg AK, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 77(3):247-253, 11/2005.
66. Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lynch PM, Rice DC, Roth JA, Ajaini JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 104(7):1349-1355, 10/2005.
67. Wang SL, Liao ZX, Liu XF, Yu ZH, Gu DZ, Qian TN, Song YW, Jin J, Wang WH, Li YX. Primary early-stage intestinal and colonic non-Hodgkin's lymphoma: clinical features, management, and outcome of 37 patients. World J Gastroenterol 11(37):5905-5909, 10/2005. PMID: 16270408.
68. Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu T-T, Morris J, Liao Z, Komaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patients with non-metastatic esophageal or gastroesophageal junction carcinoma. Cancer 104(8):1620-1626, 10/2005.
69. Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liy HH, Castillo R, Mohan R, Liao Z, Macapinlac HA. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 46(9):1481-1487, 9/2005.
70. Zhu XR, Prado K, Liu HH, Guerrero T, Jeter M, Liao Z, Rice D, Foster K, Stevens CW. Intensity-modulated radiation therapy for mesothelioma: impact of multileaf collimator leaf width and pencil beam size on planning quality and delivery efficiency. Int J Radiat Oncol Biol Phys 62(5):1525-1534, 8/2005.
71. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki R, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 241(5):810-817; 817-820, 5/2005.
72. Chang JY, Komaki R, Sasaki R, Liao Z, Stevens CW, Lu C, Fossella FV, Allen PK, Cox JD, Spitz MR, Wu X. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res 11(8):2894-2898, 4/2005.
73. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 61(3):656-664, 3/2005.
74. Rosen I, Liu H, Childress N, Liao Z. Interactively exploring optimized treatment plans. Int J Radiat Oncol Biol Phys 61(2):570-582, 2/2005.
75. Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Walsh GL, Vaporciyan AA, Rice DC, Fukami N, Roth JA, Ajani JA. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer 36(2):69-76, 2005. PMID: 16648656.

Invited Articles

1. Liao ZX, Mason KA, Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs 67:821-845, 2007.
2. Liao ZX, Cox JD, Komaki R. Radiochemotherapy of esophageal cancer. J Thorac Oncol 2:553-568, 2007.
3. Andratschke NH, Dittmann KH, Mason KA, Fan Z, Liao ZX, Komaki R, Ang KK, Milas L. Epidermal growth factor receptor as a target to improve treatment of lung cancer. Clin lung cancer 5:340-352, 2005.
4. Komaki R, Chang JY, Wu X, Allen PK, Milas L, Liao ZX, Wang X, Murshed H, Bonnen M, Garg A, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R. Mutagen sensitivity (MS) may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer (NSCLC) treated by chemoradiotherapy. Semin Oncol 32 2 Suppl 3:S92-98, 2005.
5. Milas L, Raju U, Liao ZX, Ajani J. Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol 32 Suppl 9:S78-81, 2005.

Grant & Contract Support

Title: BOI mucositis study
Funding Source: Amgen, Inc.
Role: Co-Investigator
Principal Investigator: Adam Garden
Duration: 9/1/2007 - 5/31/2011

Last updated: 2/24/2013